Antiviral Agents
Antiviral Agents
English[eng]
Zika virus||nucleoside analogues||antiviral agents||NS5||prodrugs||ProTides||neural stem cells||RNA-dependent RNA polymerase||cytomegalovirus||latent infection||TALEN||Surveyor nuclease mutation detection assay||ie-1 gene||quantitative real-time PCR||Epstein–Barr virus||herpes viruses||lytic gene expression||Burkitt lymphoma cells||clozapine||antipsychotic drug||antiviral drug||enteroviruses||coxsackievirus B4||persistent infection||fluoxetine||resistance||mutations||herpes B virus||macacine herpesvirus-1||genistein||flavonoids||acyclovir||ganciclovir||Plantago asiatica||Clerodendrum trichotomum||RSV||therapeutic effects||acteoside||human antimicrobial peptides||antiviral strategies||defensins||cathelicidins||hepcidins||transferrins||influenza A virus||brevilin A||antiviral||sesquiterpene lactone||replication||PRRSV||polyethylenimine||PEI||virion internalization||endocytosis||HIV||pediatrics||Ethiopia||pre-treatment drug resistance||combination antiretroviral therapy (cART)||dried plasma spots||dried blood spots||sphingolipids||glycosphingolipids||viruses||lipid biosynthesis||flavivirus||Japanese encephalitis virus||furin inhibitor||precursor membrane protein||measles virus||central nervous system||tropism||treatments||porcine reproductive and respiratory syndrome virus||ginsenoside Rg1||antiviral activity||pro-inflammatory factor||NF-κB signaling pathway||acute/latent infection||congenital infection||antiviral agent||therapeutic strategies||nucleic acid-based therapeutic approach||HCMV vaccine||adoptive cell therapy||Rev response element||chemical footprinting||SHAPE||drug discovery||branched peptides||herpesvirus||immediate-early||IE1||IE2||ribozyme||RNA interference||CRISPR/Cas||small molecule||orthohantavirus||phenyl-benzotriazoles||C-FRA||Porcine circovirus type 2||epigallocatechin gallate||heparan sulfate||antiviral effect||virus attachment||microvirin||lectin||human immunodeficiency virus||hepatitis C virus||antiviral inhibitor||non-immunogenic||viral entry||protein drugs||LUMS1||oleanane-type derivatives||influenza A virus (IAV)||virus entry inhibitors||hemagglutinin (HA)||n/a
English[eng]
Zika virus||nucleoside analogues||antiviral agents||NS5||prodrugs||ProTides||neural stem cells||RNA-dependent RNA polymerase||cytomegalovirus||latent infection||TALEN||Surveyor nuclease mutation detection assay||ie-1 gene||quantitative real-time PCR||Epstein–Barr virus||herpes viruses||lytic gene expression||Burkitt lymphoma cells||clozapine||antipsychotic drug||antiviral drug||enteroviruses||coxsackievirus B4||persistent infection||fluoxetine||resistance||mutations||herpes B virus||macacine herpesvirus-1||genistein||flavonoids||acyclovir||ganciclovir||Plantago asiatica||Clerodendrum trichotomum||RSV||therapeutic effects||acteoside||human antimicrobial peptides||antiviral strategies||defensins||cathelicidins||hepcidins||transferrins||influenza A virus||brevilin A||antiviral||sesquiterpene lactone||replication||PRRSV||polyethylenimine||PEI||virion internalization||endocytosis||HIV||pediatrics||Ethiopia||pre-treatment drug resistance||combination antiretroviral therapy (cART)||dried plasma spots||dried blood spots||sphingolipids||glycosphingolipids||viruses||lipid biosynthesis||flavivirus||Japanese encephalitis virus||furin inhibitor||precursor membrane protein||measles virus||central nervous system||tropism||treatments||porcine reproductive and respiratory syndrome virus||ginsenoside Rg1||antiviral activity||pro-inflammatory factor||NF-κB signaling pathway||acute/latent infection||congenital infection||antiviral agent||therapeutic strategies||nucleic acid-based therapeutic approach||HCMV vaccine||adoptive cell therapy||Rev response element||chemical footprinting||SHAPE||drug discovery||branched peptides||herpesvirus||immediate-early||IE1||IE2||ribozyme||RNA interference||CRISPR/Cas||small molecule||orthohantavirus||phenyl-benzotriazoles||C-FRA||Porcine circovirus type 2||epigallocatechin gallate||heparan sulfate||antiviral effect||virus attachment||microvirin||lectin||human immunodeficiency virus||hepatitis C virus||antiviral inhibitor||non-immunogenic||viral entry||protein drugs||LUMS1||oleanane-type derivatives||influenza A virus (IAV)||virus entry inhibitors||hemagglutinin (HA)||n/a